Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.18 USD

29.18
7,728,179

+0.21 (0.73%)

Updated Sep 27, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Analyst Reports for Pfizer, BHP Billiton & Facebook

Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), BHP Billiton (BHP) and Facebook (FB)

    Pfizer's Leukemia Candidate Gets Priority Review From FDA

    The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.

      Nitish Marwah headshot

      Will a Trade War With China Wreak Havoc in US Healthcare?

      It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

        Swarup Gupta headshot

        Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress

        The Dow endured a turbulent week, marked by lingering trade tensions.

          Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER

          Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.

            Achieve Life Sciences' Shares Rise on Positive Clinical Data

            Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.

              Merck's Keytruda Under FDA Review for Advanced Melanoma

              Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.

                Pfizer's Breast Cancer Drug Misses Overall Survival in Study

                Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.

                  Lilly Wins Favorable Ruling From U.S. Court in Alimta Row

                  Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.

                    Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI

                    Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.

                      Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil

                      Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil

                        Indrajit Bandyopadhyay headshot

                        DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

                        Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.

                          Tracey Ryniec headshot

                          How Long Should You Own a Stock?

                          These 4 criteria can guide investors through the investing maze.

                            Amgen Gets EU Nod to Add Survival Data on Blincyto's Label

                            Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.

                              Sarepta's Stock Soars on Encouraging Gene Therapy Results

                              Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

                                Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx

                                The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.

                                  Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III

                                  Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen

                                    Sarepta Inks Manufacturing Deal for Gene Therapy Program

                                    Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

                                      Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

                                      Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

                                        Kinjel Shah headshot

                                        Alzheimer's Research Stumbles Again: What's the Road Ahead?

                                        The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

                                          Indrajit Bandyopadhyay headshot

                                          JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space

                                          Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.

                                            The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty

                                            The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty

                                              Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset

                                              Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.

                                                Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant

                                                Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.

                                                  Mark Vickery headshot

                                                  Top Stock Reports for Pfizer, Union Pacific & Broadcom

                                                  Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Union Pacific (UNP) and Broadcom (AVGO).